| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
JAMA
|
2002
|
36.26
|
|
2
|
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
|
JAMA
|
2002
|
9.87
|
|
3
|
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
|
JAMA
|
2000
|
7.73
|
|
4
|
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
|
J Clin Hypertens (Greenwich)
|
2002
|
6.03
|
|
5
|
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
|
Am J Hypertens
|
1996
|
4.66
|
|
6
|
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
|
JAMA
|
2005
|
3.89
|
|
7
|
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
Circulation
|
2006
|
3.69
|
|
8
|
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Arch Intern Med
|
2005
|
3.18
|
|
9
|
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
Lancet
|
2000
|
3.01
|
|
10
|
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
|
Ann Intern Med
|
2006
|
2.81
|
|
11
|
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
|
J Clin Hypertens (Greenwich)
|
2013
|
2.64
|
|
12
|
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Circulation
|
2008
|
2.51
|
|
13
|
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2012
|
2.42
|
|
14
|
ALLHAT: setting the record straight.
|
Ann Intern Med
|
2004
|
2.19
|
|
15
|
Trends in pharmacologic management of hypertension in the United States.
|
Arch Intern Med
|
1995
|
2.04
|
|
16
|
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Arch Intern Med
|
2005
|
1.99
|
|
17
|
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Hypertension
|
2003
|
1.85
|
|
18
|
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Am J Kidney Dis
|
2008
|
1.68
|
|
19
|
The verdict from ALLHAT--thiazide diuretics are the preferred initial therapy for hypertension.
|
JAMA
|
2002
|
1.66
|
|
20
|
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
|
Clin J Am Soc Nephrol
|
2012
|
1.62
|
|
21
|
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
1.59
|
|
22
|
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
|
Circulation
|
2011
|
1.52
|
|
23
|
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
|
J Hypertens
|
2014
|
1.42
|
|
24
|
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
|
Control Clin Trials
|
2001
|
1.39
|
|
25
|
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
J Gen Intern Med
|
2008
|
1.28
|
|
26
|
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
|
J Am Coll Cardiol
|
2009
|
1.24
|
|
27
|
Calcium-channel blockers for hypertension--uncertainty continues.
|
N Engl J Med
|
1998
|
1.17
|
|
28
|
The ALLHAT lipid lowering trial--less is less.
|
JAMA
|
2002
|
1.17
|
|
29
|
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Hypertension
|
2001
|
1.15
|
|
30
|
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.
|
Curr Control Trials Cardiovasc Med
|
2002
|
1.13
|
|
31
|
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Control Clin Trials
|
2001
|
1.12
|
|
32
|
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Arch Intern Med
|
2008
|
1.09
|
|
33
|
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Diabetes Care
|
2007
|
1.07
|
|
34
|
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
Arch Intern Med
|
2004
|
1.06
|
|
35
|
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.
|
Diabetes Metab Syndr Obes
|
2014
|
1.05
|
|
36
|
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.04
|
|
37
|
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2007
|
0.95
|
|
38
|
Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
39
|
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
|
J Gen Intern Med
|
2014
|
0.91
|
|
40
|
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
|
Hypertension
|
2013
|
0.90
|
|
41
|
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
|
Ann Intern Med
|
2002
|
0.89
|
|
42
|
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
JAMA
|
2000
|
0.88
|
|
43
|
Cardiovascular risk assessment: addition of CKD and race to the Framingham equation.
|
Am Heart J
|
2012
|
0.87
|
|
44
|
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
|
J Clin Hypertens (Greenwich)
|
2004
|
0.86
|
|
45
|
Use of calcium channel blockers in hypertension.
|
Adv Intern Med
|
1998
|
0.86
|
|
46
|
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Control Clin Trials
|
2001
|
0.85
|
|
47
|
Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
J Clin Hypertens (Greenwich)
|
2003
|
0.85
|
|
48
|
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
|
J Clin Hypertens (Greenwich)
|
2009
|
0.84
|
|
49
|
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
|
PLoS One
|
2012
|
0.83
|
|
50
|
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.
|
Pharmacogenomics
|
2012
|
0.83
|
|
51
|
Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
|
JAMA Intern Med
|
2016
|
0.82
|
|
52
|
What, if anything, is controversial about calcium antagonists?
|
Am J Hypertens
|
1996
|
0.81
|
|
53
|
ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
|
Am J Hypertens
|
1996
|
0.80
|
|
54
|
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Diabetes Care
|
2001
|
0.78
|
|
55
|
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
|
J Am Soc Hypertens
|
2014
|
0.78
|
|
56
|
Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: is the obesity paradox real?
|
J Clin Hypertens (Greenwich)
|
2014
|
0.77
|
|
57
|
Recruitment of African-American patients for clinical trials--the Allhat challenges. Antihypertensive and Lipid-lowering Trial to Prevent Heart Attack.
|
J Natl Med Assoc
|
1995
|
0.77
|
|
58
|
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
|
Circulation
|
2000
|
0.76
|
|
59
|
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
|
Am J Cardiol
|
2015
|
0.75
|
|
60
|
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
|
BMC Health Serv Res
|
2016
|
0.75
|
|
61
|
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
|
Hypertension
|
2019
|
0.75
|
|
62
|
Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
Clin Exp Hypertens
|
1996
|
0.75
|
|
63
|
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
|
J Clin Hypertens (Greenwich)
|
2013
|
0.75
|
|
64
|
What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
|
J Cardiovasc Nurs
|
2003
|
0.75
|
|
65
|
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
|
Curr Hypertens Rep
|
2003
|
0.75
|
|
66
|
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
|
Clin Nephrol
|
2013
|
0.75
|
|
67
|
The ALLHAT challenges.
|
J Natl Med Assoc
|
1996
|
0.75
|
|
68
|
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
|
Curr Hypertens Rep
|
2004
|
0.75
|
|
69
|
ALLHAT and calcium channel blockers. ALLHAT Research Group.
|
Am J Hypertens
|
1997
|
0.75
|
|
70
|
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
|
Circ Cardiovasc Qual Outcomes
|
2016
|
0.75
|
|
71
|
Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
|
JAMA Intern Med
|
2016
|
0.75
|